Physician profile
Laura Williams
NPI 1508453671
$4,773.01
in general payments reported to CMS, 2019-2025
42 companies · $2,574 in 2025
The $2,574 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $325 · 2022: $466 · 2023: $307 · 2024: $1,099 · 2025: $2,574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,981.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $845.12 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $324.09 | 2021-2025 | Xifaxan |
| Janssen Biotech, INC. | $301.82 | 2025 | Tremfya |
| Amgen INC. | $274.67 | 2021-2024 | Repatha, Otezla, Prolia |
| Lilly USA, LLC | $250.18 | 2023-2025 | Omvoh, Mounjaro, Zepbound |
| Novo Nordisk INC | $234.35 | 2021-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $233.55 | 2023-2024 | |
| Ardelyx, INC. | $222.51 | 2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $218.57 | 2021-2025 | Entyvio |
| Celltrion USA INC. | $192.27 | 2025 | Vegzelma |
| Medtronic, INC. | $136.32 | 2024 | Signia |
| Teva Pharmaceuticals USA, INC. | $115.31 | 2023-2024 | Austedo Xr |
| Genzyme Corporation | $110.02 | 2025 | |
| Intercept Pharmaceuticals, INC. | $98.54 | 2025 | |
| Janssen Pharmaceuticals, INC | $96.08 | 2021-2024 | Xarelto |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.